0001437749-23-033803.txt : 20231206
0001437749-23-033803.hdr.sgml : 20231206
20231206195450
ACCESSION NUMBER: 0001437749-23-033803
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231204
FILED AS OF DATE: 20231206
DATE AS OF CHANGE: 20231206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DUGGAN ROBERT W
CENTRAL INDEX KEY: 0001055919
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37744
FILM NUMBER: 231470849
MAIL ADDRESS:
STREET 1: 611 SOUTH FORT HARRISON AVE
STREET 2: SUITE 306
CITY: CLEARWATER
STATE: FL
ZIP: 33756
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pulse Biosciences, Inc.
CENTRAL INDEX KEY: 0001625101
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 465696597
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3957 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: 510-906-4600
MAIL ADDRESS:
STREET 1: 3957 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
FORMER COMPANY:
FORMER CONFORMED NAME: Electroblate, Inc.
DATE OF NAME CHANGE: 20141113
4
1
rdgdoc.xml
FORM 4
X0508
4
2023-12-04
0001625101
Pulse Biosciences, Inc.
PLSE
0001055919
DUGGAN ROBERT W
3957 POINT EDEN WAY
HAYWARD
CA
94545
1
1
0
Common Stock
2023-12-04
4
M
0
20000
10.66
A
36571461
D
Common Stock
2023-12-04
4
M
0
20347
10.66
A
36591808
D
Common Stock
2023-12-04
4
P
0
27000
10.38
A
285544
I
See footnote
Common Stock
492069
I
See footnote
Stock Option (right to buy)
10.66
2023-12-04
4
M
0
20000
0
D
2030-05-18
Common Stock
20000
0
D
Stock Option (right to buy)
10.66
2023-12-04
4
M
0
20347
0
D
2030-05-18
Common Stock
20347
0
D
Volume-weighted average price.
Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder.
Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a monthly basis following the Company's 2020 Annual Stockholder Meeting.
Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a quarterly basis following the Company's 2020 Annual Stockholder Meeting.
/s/ Kenneth B. Stratton, as Attorney-in-Fact
2023-12-06